107 related articles for article (PubMed ID: 32343987)
21. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.
Zajac M; Gomez G; Benitez J; Martínez-Delgado B
BMC Med Genomics; 2010 Oct; 3():44. PubMed ID: 20920318
[TBL] [Abstract][Full Text] [Related]
22. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
[TBL] [Abstract][Full Text] [Related]
23. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
24. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
26. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
27. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
Cui Y; Wu W; Zhou Y; Xie Q; Liu T; Jin J; Liu K
Future Oncol; 2013 Mar; 9(3):411-8. PubMed ID: 23469976
[TBL] [Abstract][Full Text] [Related]
28. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
[TBL] [Abstract][Full Text] [Related]
30. [Effects of 17-DMAG on non-small cell lung cancer cell lines A549 and H1975
being resistant to EGFR-TKI].
Zhao L; Cao F
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):778-82. PubMed ID: 25404267
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin abrogates the geldanamycin-induced heat shock response.
McCollum AK; Lukasiewicz KB; Teneyck CJ; Lingle WL; Toft DO; Erlichman C
Mol Cancer Ther; 2008 Oct; 7(10):3256-64. PubMed ID: 18852129
[TBL] [Abstract][Full Text] [Related]
32. Discovery and synthesis of 3- and 21-substituted fusidic acid derivatives as reversal agents of P-glycoprotein-mediated multidrug resistance.
Guo M; Ren Q; Wang B; Ji W; Ni J; Feng Y; Bi Y; Tian J; Wang H
Eur J Med Chem; 2019 Nov; 182():111668. PubMed ID: 31505451
[TBL] [Abstract][Full Text] [Related]
33. Novel virosecurinine bivalent mimetics as potent reversal agents against P-glycoprotein-mediated multidrug resistance.
Hou W; Meng Y; Xu XF; Huang ZX; Liu J; Wang ZY; Lin J; Chen WM
Eur J Med Chem; 2019 Dec; 183():111726. PubMed ID: 31585275
[TBL] [Abstract][Full Text] [Related]
34. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Lombardi R; Sonego M; Pucci B; Addi L; Iannelli F; Capone F; Alfano L; Roca MS; Milone MR; Moccia T; Costa A; Di Gennaro E; Bruzzese F; Baldassarre G; Budillon A
Mol Oncol; 2021 Apr; 15(4):1005-1023. PubMed ID: 33331136
[TBL] [Abstract][Full Text] [Related]
35. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
36. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
37. Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.
Mo Q; Zhang Y; Jin X; Gao Y; Wu Y; Hao X; Gao Q; Chen P
Tumour Biol; 2016 Nov; 37(11):14745-14755. PubMed ID: 27629142
[TBL] [Abstract][Full Text] [Related]
38. Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis.
Grieve S; Gao Y; Hall C; Hu J; Greer PA
Mol Cell Biol; 2016 Aug; 36(15):2078-88. PubMed ID: 27215381
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
40. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
Solárová Z; Mojžiš J; Solár P
Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
